Drugs / H5N1 Antigen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01317745 | May 2011 → Sep 2012 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06560151 | Aug 2024 → Jan 2025 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5N1 antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06560151 ↗ |
| Known as | Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) | “This treatment group of 60 participants (ages 18-64) will receive 3.75 µg of Egg-A/bar-headed goose/Qinghai Lake/1A/2005 (H5N1) adjuvanted with a full dose of AS03A.” NCT06560151 ↗ |
| Modality | Vaccine | “intramuscular subvirion inactivated monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005) virus vaccine” NCT01317745 ↗ |
| Route | Intramuscular | “intramuscular subvirion inactivated monovalent influenza A/H5N1” NCT01317745 ↗ |